Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.

摘要: The clinical success of mAbs continues to reinforce antibody engineering as an essential tool for the development biologics. Research focused on discovering next generation therapeutics has prompted a revisiting concept bispecific antibodies (bsAbs). Recently, programs investigating combinations mAb therapies have renewed interest in applications bsAbs. However, because challenges with production, efforts directed toward bsAbs yet yield product approved by FDA. current status these proteins implies that strategies constructing therapeutic will likely require highly refined design plan at outset process. Antibody fragments are attractive building blocks assembly Of recombinant fragments, single-chain variable (scFvs) offer advantage expression single polypeptide, thereby greatly simplifying production. issues stability plagued and limit application scFvs therapeutics. Recent advances selection processes using display platforms been reported facilitate 'evolution' obtain stabilities comparable those mAbs. timely scFv parallel resurgence enable construction dual-targeting can be manufactured